Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 4/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | ICMT | O60725 | 3/20 | 0.34 |
| ▸ | BACE1 | P56817 | 6/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.31 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.31 |
| ▸ | TSPO | P30536 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4236897 | 0.92 | BACE1 (0.34) | BACE1L3MBTL1ATM | |
| SCHEMBL4238299 | 0.91 | BACE1 (0.39) | BACE1L3MBTL1ATM | |
| SCHEMBL4238078 | 0.90 | BACE1 (0.38) | BACE1L3MBTL1ATM | |
| SCHEMBL4232737 | 0.90 | BACE1 (0.38) | BACE1 | |
| SCHEMBL4232217 | 0.89 | HSD11B1 (0.36) | BACE1 | |
| SCHEMBL4238420 | 0.88 | BACE1 (0.35) | BACE1 | |
| SCHEMBL4242601 | 0.87 | PTPN5 (0.35) | BACE1ATM | |
| SCHEMBL4237040 | 0.87 | HSD11B1 (0.34) | BACE1 | |
| SCHEMBL4232074 | 0.86 | DHODH (0.36) | BACE1 | |
| SCHEMBL4236592 | 0.86 | BACE1 (0.34) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176850-A1 | Novel 2-Amino-Imidazole-4-One Compounds And Their Use In The Manufacture Of A Medicament To Be Used In The Treatment Of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration And Dementia | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | claimed |
| US-20090176850-A1 | Novel 2-Amino-Imidazole-4-One Compounds And Their Use In The Manufacture Of A Medicament To Be Used In The Treatment Of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration And Dementia | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176850-A1 | Novel 2-Amino-Imidazole-4-One Compounds And Their Use In The Manufacture Of A Medicament To Be Used In The Treatment Of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration And Dementia | PSEN2, MAPT, PSEN1 | PGR 4520/4885MDM2 2162/4885ICMT 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.